Aktuellt
SENASTE
Redeye comments on the postponement of PANTAX phase Ib top-line data into Q2 or Q3 2022. We judge this does not change the investment case longer-term, though it will probably mean that SCO-101’s development in pancreatic cancer proceeds slower than we initially expected. PANTAX phase Ib readout was our only expected catalyst during Q4 2021, and the share opened down some 20% this morning.
LÄS MER
